{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-22-000057","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2022-06-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.219615+00:00","generated_at":"2026-06-25T03:35:34.054928+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunovant gains FDA alignment for Phase 3 batoclimab trials in TED; reports FY2022 loss of $156.7M","bullets":["FDA aligned on Phase 3 TED program: two placebo-controlled trials (100 patients each) initiating H2 2022; top-line data H1 2025.","Phase 3 MG trial initiation on track by end of June 2022; top-line data expected H2 2024.","Cash $493.8M as of March 31, 2022 provides runway into calendar year 2025.","FY2022 net loss $156.7M ($1.43/share) vs FY2021 $107.4M ($1.22/share); R&D spend $101.8M.","Company expects to announce two new batoclimab indications by August 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-22-000057","json":"https://secwatch.observer/filing/0001764013-22-000057.json","markdown":"https://secwatch.observer/filing/0001764013-22-000057.md","text":"https://secwatch.observer/filing/0001764013-22-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000057/0001764013-22-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000057/imvt-20220608.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T03:35:34.054928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}